The research of targeting tumor-associated dendritic cells, a new therapy strategy by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses

• Project/Area Number: 23K14668
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: National Center for Child Health and Development
• Principal Investigator: Hu Xin 国立研究開発法人国立成育医療研究センター, 移植免疫研究室, リサーチアソシエイト (40868965)
• Project Period (FY): 2023-04-01 – 2025-03-31
• Project Status: Granted (Fiscal Year 2023)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2024: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000); Fiscal Year 2023: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: cancer immunotherapy / combined phospholipids / TADCs / TILs / tumor microenvironment

Outline of Research at the Start

Targeting TADCs may provide effective immunotherapy for cancer.PS can enhance the recognition, processing and antigen presentation of DC. We will focus on how to improve the efficacy of the TADCs anti-tumor therapy with the phospholipids treatment and their synergistic effects mechanism.